Skip to main content
. Author manuscript; available in PMC: 2012 Jan 25.
Published in final edited form as: Eur J Pharmacol. 2011 Jan 25;651(1-3):96–105. doi: 10.1016/j.ejphar.2010.10.085

Fig. 1.

Fig. 1

Effects of O-2050 (i.v.) across a wide dose range on percentage antagonism of hypomobility (top panel), antinociception (middle panel) and hypothermia (bottom panel) produced by 3 mg/kg (i.v.) Δ9-tetrahydrocannabinol in mice (n=5-6 mice/dose combination).